Speaking Engagement

Dean Fanelli, Jamaica Szeliga and Parithosh Tungaturthi to Present "Trends in Paragraph IV Challenges: What Lies Ahead in 2017 and Beyond LIVE Webcast"

5/24/2017

Webinar

Wednesday, May 24, 2017
11:00 a.m. to 1:00 p.m. EST

Dean Fanelli, Jamaica Szeliga and Parithosh Tungaturthi will be presenting "Trends in Paragraph IV Challenges: What Lies Ahead in 2017 and Beyond LIVE Webcast," presented by The Knowledge Group LLC Live Webast Seriies, on May 24, 2017.
 
The Hatch-Waxman Act encourages generic drug manufacturers to challenge active drug patents and gain market entry before those patents expire. The generic company, who is the first to file its Abbreviated New Drug Application (ANDA) with a Paragraph IV certification and prevails subsequent lawsuit, is granted 180 days of market exclusivity. This is a valuable opportunity that attracted many generic drug manufacturers – like Teva, Actavis, Mylan, and Sandoz – to be aggressively involved in Paragraph IV filings.
 
Over the years, the percentage of brand name drugs facing Paragraph IV patent challenge has increased. Additionally, patent challenges occur much earlier in time after the branded product is approved and launched.
 
In this two-hour LIVE Webcast, a panel of distinguished professionals and thought leaders organized by The Knowledge Group will provide the audience with an analysis of the recent trends in Paragraph IV patent challenges. They will also discuss significant court decisions and settlement outcomes on patent challenges.
 
Key topics include:
  • Important rule changes
  • What’s pending in the courts at various levels
  • Supreme Court treatment in these matters
  • Guidelines for providing notice
  • Practice tips IPR’s and ANDA litigations
  • Recent Trends on Patent Challenges
  • Factors Influencing These Trends
  • Paragraph IV Court Decisions and Settlements


For more information, click here.

Register for this webinar.